Perjeta regimen shows long-term value in early breast cancer

Long-term data from the Phase III APHINITY study support the use of a Perjeta-based regimen in HER2-positive early breast cancer.

The study examines a combination of Roche’s (ROG: SIX) Perjeta (pertuzumab) and Herceptin (trastuzumab), with chemotherapy, compared with Herceptin and chemo plus a placebo.

People in the trial were given treatment after surgery, and were deemed to be at high risk of recurrence. Globally, more than 500,000 people who fit into this category have received the Perjeta-based regimen, indicating the scale of the treatment opportunity for Roche.